feedback
The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

Activity Details

Free Activity
Released: August 2, 2017
Expires: August 2, 2018
30 minutes to complete

Target Audience

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Examine the role of cyclins and cyclin-dependent kinases in the biology of ER-positive disease and the mechanism of action of the range of CDK4/6 inhibitors in development
  • Summarize the clinical application of novel combinations of targeted and endocrine therapy for the first- and second-line treatment of ER-positive, HER2-negative advanced breast cancer
  • Select appropriate treatment combinations for ER-positive, HER2-negative breast cancer, and identify the optimal sequence of treatment options

Activity Description

Update your treatment options with this breast cancer thought-leader discussion, with associated slide deck and eNewsflash, featuring valuable updates and expert perspectives on exciting new developments in the management of breast cancer released at the 2017 Oncology Annual Meeting in Chicago.

Agenda

FEATURED ABSTRACTS

Abstract #1000: 
MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy

Abstract #1001: 
Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)

Abstract #1002: 
A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2-negative (HER2-) metastatic breast cancer (mBC) (TREnd trial)

Abstract #1010: 
Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC): First- and second-line data from the BOLERO-4 study

Abstract #1018: 
Predicting sensitivity to palbociclib with early circulating tumor DNA dynamics in the PALOMA-3 trial

Abstract #1019: 
Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2-negative breast cancer

Abstract #1020: 
Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from MONALEESA-2

Abstract #1038: 
Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC)

Abstract #1047: 
First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results

Abstract #1050: 
Predictors of prolonged benefit from palbociclib (PAL) plus fulvestrant (F) in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2-) advanced breast cancer (ABC) in PALOMA-3

Faculty

Robert Coleman, MD, FRCP, FRCPE
Medical Director, prIME Oncology
University of Sheffield
Weston Park Hospital
Sheffield, United Kingdom


Angelo Di Leo, MD, PhD
Istituto Toscano Tumori, Hospital of Prato
Prato, Italy


Joyce O’Shaughnessy, MD
Baylor University Medical Center
Texas Oncology
US Oncology
Dallas, Texas, United States


Statement of Commercial Support

This educational activity is supported by a grant from Novartis Oncology.

Hardware / Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.